Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Analysts
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) has been given a consensus recommendation of “Buy” by the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […]
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) has been given a consensus recommendation of “Buy” by the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […]
